INmune Bio, Inc. (INMB)
1.26
+0.05
(+4.13%)
USD |
NASDAQ |
Jun 11, 13:32
INmune Bio Profit Margin (Quarterly)
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2025 | -19.48K% |
| December 31, 2024 | |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | -78.75K% |
| December 31, 2023 | -30.03K% |
| September 30, 2023 | -19.91K% |
| June 30, 2023 | -14.13K% |
| March 31, 2023 | -17.20K% |
| Date | Value |
|---|---|
| December 31, 2022 | -6.01K% |
| September 30, 2022 | -7.88K% |
| June 30, 2022 | -42.74K% |
| March 31, 2022 | -4.23K% |
| December 31, 2021 | -5.93K% |
| September 30, 2021 | -67.56K% |
| June 30, 2021 | |
| March 31, 2021 | -113.9K% |
| December 31, 2020 | -29.40K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Sangamo Therapeutics, Inc. | -2.15K% |
| Arrowhead Pharmaceuticals, Inc. | -186.6% |
| Oncolytics Biotech, Inc. | -- |
| Sarepta Therapeutics, Inc. | 45.29% |
| Anixa Biosciences, Inc. | -- |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -163.7% |
| Return on Assets | -124.5% |
| Return on Invested Capital | -158.2% |
| Return on Net Operating Assets | -866.8% |